INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 32 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2019 | $10,579,000 | – | 10,650,000 | – | 0.31% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Context Capital Management, LLC | 2,500,000 | $2,486,000 | 1.44% |
HIGHBRIDGE CAPITAL MANAGEMENT LLC | 20,000,000 | $19,894,000 | 1.32% |
SSI INVESTMENT MANAGEMENT LLC | 6,154,000 | $6,089,000 | 0.45% |
CSS LLC/IL | 7,750,000 | $7,713,000 | 0.44% |
Senvest Management, LLC | 5,000,000 | $4,998,000 | 0.44% |
Antara Capital LP | 2,000,000 | $1,989,000 | 0.43% |
LINDEN ADVISORS LP | 28,527,000 | $28,380,000 | 0.43% |
Graham Capital Management, L.P. | 10,650,000 | $10,579,000 | 0.31% |
WOLVERINE ASSET MANAGEMENT LLC | 19,000,000 | $18,904,000 | 0.25% |
Polar Asset Management Partners Inc. | 10,000,000 | $9,957,000 | 0.18% |